Precose, (acarbose) dosing, indications, interactions, adverse effects, and more (original) (raw)

All Interactions Sort By:

Contraindicated (0)

Serious (2)

• ethanol
  ethanol, acarbose. Other (see comment). Contraindicated. Comment: Excessive EtOH consumption may alter glycemic control. Some sulfonylureas may produce a disulfiram like rxn.
• pramlintide
  pramlintide, acarbose. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI nutrient absorption.

Monitor Closely (59)

• albiglutide
  albiglutide, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.
• aripiprazole
  aripiprazole, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
• asenapine
  asenapine, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
• atazanavir
  atazanavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.
• bitter melon
  bitter melon increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.
• cinnamon
  cinnamon increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.
• ciprofloxacin
  ciprofloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. .
• clozapine
  acarbose, clozapine. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
• darunavir
  darunavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.
• digoxin
  acarbose will decrease the level or effect of digoxin by unspecified interaction mechanism. Use Caution/Monitor. Measure serum digoxin concentrations before initiating concomitant drugs; continue monitoring and increase digoxin dose by approximately 20% to 40% as necessary
• dulaglutide
  dulaglutide, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• exenatide injectable solution
  exenatide injectable solution, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.
• exenatide injectable suspension
  exenatide injectable suspension, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.
• fleroxacin
  fleroxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
• fosamprenavir
  fosamprenavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.
• gemifloxacin
  gemifloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
• iloperidone
  iloperidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
• insulin aspart
  acarbose, insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin aspart protamine/insulin aspart
  acarbose, insulin aspart protamine/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin degludec
  acarbose, insulin degludec. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin degludec/insulin aspart
  acarbose, insulin degludec/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin detemir
  acarbose, insulin detemir. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin glargine
  acarbose, insulin glargine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin glulisine
  acarbose, insulin glulisine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin inhaled
  acarbose, insulin inhaled. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin isophane human/insulin regular human
  acarbose, insulin isophane human/insulin regular human. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin lispro
  acarbose, insulin lispro. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin lispro protamine/insulin lispro
  acarbose, insulin lispro protamine/insulin lispro. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin NPH
  acarbose, insulin NPH. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• insulin regular human
  acarbose, insulin regular human. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.
• ketotifen, ophthalmic
  ketotifen, ophthalmic, acarbose. Other (see comment). Use Caution/Monitor. Comment: Combination may result in thrombocytopenia (rare). Monitor CBC.
• letermovir
  letermovir will increase the level or effect of acarbose by unspecified interaction mechanism. Use Caution/Monitor. Monitor glucose concentrations
• levofloxacin
  levofloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
• liraglutide
  liraglutide, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.
• lonapegsomatropin
  lonapegsomatropin decreases effects of acarbose by Other (see comment). Modify Therapy/Monitor Closely. Comment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents.lonapegsomatropin decreases effects of acarbose by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone (GH) analogs may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating growth hormone.
• lopinavir
  lopinavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.
• lurasidone
  lurasidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
• marijuana
  marijuana decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor.
• mecasermin
  mecasermin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.
• mipomersen
  mipomersen, acarbose. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.
• moxifloxacin
  moxifloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
• nelfinavir
  nelfinavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.
• ofloxacin
  ofloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.
• olanzapine
  olanzapine, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
• opuntia ficus indica
  opuntia ficus indica increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor.
• paliperidone
  paliperidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
• pancrelipase
  pancrelipase decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. Antihyperglycemic action of acarbose results from a competitive, reversible inhibition of pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolase enzymes.
• quetiapine
  quetiapine, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
• risperidone
  risperidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.
• ritonavir
  ritonavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.
• shark cartilage
  shark cartilage increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.
• somapacitan
  somapacitan decreases effects of acarbose by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone (GH) analogs may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating growth hormone.
• somatrogon
  somatrogon decreases effects of acarbose by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone (GH) analogs may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating growth hormone.
• somatropin
  somatropin decreases effects of acarbose by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone (GH) analogs may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating growth hormone.
• sulfamethoxypyridazine
  sulfamethoxypyridazine increases effects of acarbose by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.
• tipranavir
  tipranavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.
• triamcinolone acetonide injectable suspension
  triamcinolone acetonide injectable suspension decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully.
• xipamide
  xipamide decreases levels of acarbose by increasing renal clearance. Use Caution/Monitor.
• ziprasidone
  ziprasidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

Minor (69)

• activated charcoal
  activated charcoal decreases levels of acarbose by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

• agrimony
  agrimony increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• American ginseng
  American ginseng increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• amitriptyline
  amitriptyline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• amoxapine
  amoxapine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• anamu
  anamu increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

• bendroflumethiazide
  bendroflumethiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• budesonide
  budesonide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• chlorothiazide
  chlorothiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• chlorthalidone
  chlorthalidone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• chromium
  chromium increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• clomipramine
  clomipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• clonidine
  clonidine decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.clonidine, acarbose. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

• cornsilk
  cornsilk increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• cortisone
  cortisone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• cyclopenthiazide
  cyclopenthiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• damiana
  damiana decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction.

• danazol
  danazol increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• deflazacort
  deflazacort decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• desipramine
  desipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• devil's claw
  devil's claw increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• dexamethasone
  dexamethasone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• doxepin
  doxepin increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• elderberry
  elderberry increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (in vitro research).

• eucalyptus
  eucalyptus increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

• fludrocortisone
  fludrocortisone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• fluoxymesterone
  fluoxymesterone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• fo-ti
  fo-ti increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• forskolin
  forskolin increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Colenol, a compound found in Coleus root, may stimulate insulin release.

• gotu kola
  gotu kola increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

• guanfacine
  guanfacine decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.guanfacine, acarbose. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

• gymnema
  gymnema increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• horse chestnut seed
  horse chestnut seed increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• hydrochlorothiazide
  hydrochlorothiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• hydrocortisone
  hydrocortisone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• imipramine
  imipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• indapamide
  indapamide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• isoniazid
  isoniazid decreases effects of acarbose by unspecified interaction mechanism. Minor/Significance Unknown.

• juniper
  juniper increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• lofepramine
  lofepramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• lycopus
  lycopus increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• maitake
  maitake increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (animal research).

• maprotiline
  maprotiline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• mesterolone
  mesterolone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• methyclothiazide
  methyclothiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• methylprednisolone
  methylprednisolone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• methyltestosterone
  methyltestosterone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• metolazone
  metolazone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• nettle
  nettle increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

• nortriptyline
  nortriptyline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• ofloxacin
  ofloxacin, acarbose. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.

• oxandrolone
  oxandrolone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• oxymetholone
  oxymetholone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• pegvisomant
  pegvisomant increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• potassium acid phosphate
  potassium acid phosphate increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• potassium chloride
  potassium chloride increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• potassium citrate
  potassium citrate increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• prednisolone
  prednisolone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• prednisone
  prednisone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• protriptyline
  protriptyline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• sage
  sage increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• stevia
  stevia increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• testosterone
  testosterone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• testosterone buccal system
  testosterone buccal system increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• testosterone topical
  testosterone topical increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• tongkat ali
  tongkat ali increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypoglycemia.

• trazodone
  trazodone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• trimipramine
  trimipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• vanadium
  vanadium increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• activated charcoal
  Minor (1)activated charcoal decreases levels of acarbose by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

• agrimony
  Minor (1)agrimony increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• albiglutide
  Monitor Closely (1)albiglutide, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.

• American ginseng
  Minor (1)American ginseng increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• amitriptyline
  Minor (1)amitriptyline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• amoxapine
  Minor (1)amoxapine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• anamu
  Minor (1)anamu increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

• aripiprazole
  Monitor Closely (1)aripiprazole, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• asenapine
  Monitor Closely (1)asenapine, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• atazanavir
  Monitor Closely (1)atazanavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.

• bendroflumethiazide
  Minor (1)bendroflumethiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• bitter melon
  Monitor Closely (1)bitter melon increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.

• budesonide
  Minor (1)budesonide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• chlorothiazide
  Minor (1)chlorothiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• chlorthalidone
  Minor (1)chlorthalidone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• chromium
  Minor (1)chromium increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• cinnamon
  Monitor Closely (1)cinnamon increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.

• ciprofloxacin
  Monitor Closely (1)ciprofloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. .

• clomipramine
  Minor (1)clomipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• clonidine
  Minor (2)clonidine decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.
  clonidine, acarbose. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

• clozapine
  Monitor Closely (1)acarbose, clozapine. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• cornsilk
  Minor (1)cornsilk increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• cortisone
  Minor (1)cortisone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• cyclopenthiazide
  Minor (1)cyclopenthiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• damiana
  Minor (1)damiana decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction.

• danazol
  Minor (1)danazol increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• darunavir
  Monitor Closely (1)darunavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.

• deflazacort
  Minor (1)deflazacort decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• desipramine
  Minor (1)desipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• devil's claw
  Minor (1)devil's claw increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• dexamethasone
  Minor (1)dexamethasone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• digoxin
  Monitor Closely (1)acarbose will decrease the level or effect of digoxin by unspecified interaction mechanism. Use Caution/Monitor. Measure serum digoxin concentrations before initiating concomitant drugs; continue monitoring and increase digoxin dose by approximately 20% to 40% as necessary

• doxepin
  Minor (1)doxepin increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• dulaglutide
  Monitor Closely (1)dulaglutide, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• elderberry
  Minor (1)elderberry increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (in vitro research).

• ethanol
  Serious - Use Alternative (1)ethanol, acarbose. Other (see comment). Contraindicated. Comment: Excessive EtOH consumption may alter glycemic control. Some sulfonylureas may produce a disulfiram like rxn.

• eucalyptus
  Minor (1)eucalyptus increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

• exenatide injectable solution
  Monitor Closely (1)exenatide injectable solution, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.

• exenatide injectable suspension
  Monitor Closely (1)exenatide injectable suspension, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.

• fleroxacin
  Monitor Closely (1)fleroxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• fludrocortisone
  Minor (1)fludrocortisone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• fluoxymesterone
  Minor (1)fluoxymesterone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• fo-ti
  Minor (1)fo-ti increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• forskolin
  Minor (1)forskolin increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Colenol, a compound found in Coleus root, may stimulate insulin release.

• fosamprenavir
  Monitor Closely (1)fosamprenavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.

• gemifloxacin
  Monitor Closely (1)gemifloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• gotu kola
  Minor (1)gotu kola increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

• guanfacine
  Minor (2)guanfacine decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.
  guanfacine, acarbose. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

• gymnema
  Minor (1)gymnema increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• horse chestnut seed
  Minor (1)horse chestnut seed increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• hydrochlorothiazide
  Minor (1)hydrochlorothiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• hydrocortisone
  Minor (1)hydrocortisone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• iloperidone
  Monitor Closely (1)iloperidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• imipramine
  Minor (1)imipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• indapamide
  Minor (1)indapamide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• insulin aspart
  Monitor Closely (1)acarbose, insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin aspart protamine/insulin aspart
  Monitor Closely (1)acarbose, insulin aspart protamine/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin degludec
  Monitor Closely (1)acarbose, insulin degludec. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin degludec/insulin aspart
  Monitor Closely (1)acarbose, insulin degludec/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin detemir
  Monitor Closely (1)acarbose, insulin detemir. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin glargine
  Monitor Closely (1)acarbose, insulin glargine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin glulisine
  Monitor Closely (1)acarbose, insulin glulisine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin inhaled
  Monitor Closely (1)acarbose, insulin inhaled. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin isophane human/insulin regular human
  Monitor Closely (1)acarbose, insulin isophane human/insulin regular human. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin lispro
  Monitor Closely (1)acarbose, insulin lispro. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin lispro protamine/insulin lispro
  Monitor Closely (1)acarbose, insulin lispro protamine/insulin lispro. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin NPH
  Monitor Closely (1)acarbose, insulin NPH. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin regular human
  Monitor Closely (1)acarbose, insulin regular human. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• isoniazid
  Minor (1)isoniazid decreases effects of acarbose by unspecified interaction mechanism. Minor/Significance Unknown.

• juniper
  Minor (1)juniper increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• ketotifen, ophthalmic
  Monitor Closely (1)ketotifen, ophthalmic, acarbose. Other (see comment). Use Caution/Monitor. Comment: Combination may result in thrombocytopenia (rare). Monitor CBC.

• letermovir
  Monitor Closely (1)letermovir will increase the level or effect of acarbose by unspecified interaction mechanism. Use Caution/Monitor. Monitor glucose concentrations

• levofloxacin
  Monitor Closely (1)levofloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• liraglutide
  Monitor Closely (1)liraglutide, acarbose. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.

• lofepramine
  Minor (1)lofepramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• lonapegsomatropin
  Monitor Closely (2)lonapegsomatropin decreases effects of acarbose by Other (see comment). Modify Therapy/Monitor Closely. Comment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents.
  lonapegsomatropin decreases effects of acarbose by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone (GH) analogs may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating growth hormone.

• lopinavir
  Monitor Closely (1)lopinavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.

• lurasidone
  Monitor Closely (1)lurasidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• lycopus
  Minor (1)lycopus increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• maitake
  Minor (1)maitake increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (animal research).

• maprotiline
  Minor (1)maprotiline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• marijuana
  Monitor Closely (1)marijuana decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor.

• mecasermin
  Monitor Closely (1)mecasermin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.

• mesterolone
  Minor (1)mesterolone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• methyclothiazide
  Minor (1)methyclothiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• methylprednisolone
  Minor (1)methylprednisolone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• methyltestosterone
  Minor (1)methyltestosterone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• metolazone
  Minor (1)metolazone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• mipomersen
  Monitor Closely (1)mipomersen, acarbose. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.

• moxifloxacin
  Monitor Closely (1)moxifloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• nelfinavir
  Monitor Closely (1)nelfinavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.

• nettle
  Minor (1)nettle increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

• nortriptyline
  Minor (1)nortriptyline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• ofloxacin
  Monitor Closely (1)ofloxacin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.Minor (1)ofloxacin, acarbose. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.

• olanzapine
  Monitor Closely (1)olanzapine, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• opuntia ficus indica
  Monitor Closely (1)opuntia ficus indica increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor.

• oxandrolone
  Minor (1)oxandrolone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• oxymetholone
  Minor (1)oxymetholone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• paliperidone
  Monitor Closely (1)paliperidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• pancrelipase
  Monitor Closely (1)pancrelipase decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. Antihyperglycemic action of acarbose results from a competitive, reversible inhibition of pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolase enzymes.

• pegvisomant
  Minor (1)pegvisomant increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• potassium acid phosphate
  Minor (1)potassium acid phosphate increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• potassium chloride
  Minor (1)potassium chloride increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• potassium citrate
  Minor (1)potassium citrate increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• pramlintide
  Serious - Use Alternative (1)pramlintide, acarbose. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI nutrient absorption.

• prednisolone
  Minor (1)prednisolone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• prednisone
  Minor (1)prednisone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.

• protriptyline
  Minor (1)protriptyline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• quetiapine
  Monitor Closely (1)quetiapine, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• risperidone
  Monitor Closely (1)risperidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• ritonavir
  Monitor Closely (1)ritonavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.

• sage
  Minor (1)sage increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• shark cartilage
  Monitor Closely (1)shark cartilage increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.

• somapacitan
  Monitor Closely (1)somapacitan decreases effects of acarbose by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone (GH) analogs may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating growth hormone.

• somatrogon
  Monitor Closely (1)somatrogon decreases effects of acarbose by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone (GH) analogs may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating growth hormone.

• somatropin
  Monitor Closely (1)somatropin decreases effects of acarbose by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone (GH) analogs may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating growth hormone.

• stevia
  Minor (1)stevia increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• sulfamethoxypyridazine
  Monitor Closely (1)sulfamethoxypyridazine increases effects of acarbose by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• testosterone
  Minor (1)testosterone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• testosterone buccal system
  Minor (1)testosterone buccal system increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• testosterone topical
  Minor (1)testosterone topical increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• tipranavir
  Monitor Closely (1)tipranavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset or exacerbation of diabetes mellitus and hyperglycemia have been reported with protease inhibitors.

• tongkat ali
  Minor (1)tongkat ali increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypoglycemia.

• trazodone
  Minor (1)trazodone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• triamcinolone acetonide injectable suspension
  Monitor Closely (1)triamcinolone acetonide injectable suspension decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully.

• trimipramine
  Minor (1)trimipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• vanadium
  Minor (1)vanadium increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

• xipamide
  Monitor Closely (1)xipamide decreases levels of acarbose by increasing renal clearance. Use Caution/Monitor.

• ziprasidone
  Monitor Closely (1)ziprasidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.